Indivior Pharmaceuticals (INDV) vs Telix Pharmaceuticals (TLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Indivior Pharmaceuticals (INDV) has outperformed Telix Pharmaceuticals (TLX) over the past year, gaining 52.3% versus a gain of 11.8%. Indivior Pharmaceuticals is the larger company by market cap ($4.18 billion vs $3.74 billion), about 1.1 times the size, while Telix Pharmaceuticals is growing revenue faster (+55.6% vs +4.3%). On valuation, Indivior Pharmaceuticals trades at a lower trailing P/E (12.7x vs 110.1x for Telix Pharmaceuticals).
Indivior Pharmaceuticals converts more of its revenue into profit, with a net margin of 16.9% versus -0.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDV | TLX |
|---|---|---|
| Share price | $35.45 | $11.01 |
| Market cap | $4.18B | $3.74B |
| 1-day change | -1.88% | -0.99% |
| YTD return | +0.70% | +48.46% |
| 1-year return | +52.32% | +11.76% |
| 5-year return | +127.95% | — |
| P/E ratio (TTM) | 12.71 | 110.10 |
| Forward P/E | 7.26 | — |
| EPS (TTM) | $2.79 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.24B | $803.79M |
| Revenue growth (YoY) | +4.29% | +55.61% |
| Net income (latest FY) | $210.00M | $-7.13M |
| Gross margin | 80.23% | 53.05% |
| Operating margin | 21.15% | 3.70% |
| Net margin | 16.95% | -0.89% |
| 52-week high | $42.81 | $13.11 |
| 52-week low | $22.95 | $6.28 |
| Distance from 52-week high | -17.19% | -16.02% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +38.22% | +85.47% |
| Average volume | 2.08M | 258.23K |
| Shares outstanding | 118.03M | 339.78M |
| Employees | 827 | 1,120 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDV has outperformed TLX by 40.6 percentage points over the past year.
- Telix Pharmaceuticals trades at a higher earnings multiple (110.1x vs 12.7x trailing P/E).
- Indivior Pharmaceuticals is more profitable, keeping 16.9 cents of every revenue dollar as net income versus -0.9 cents for Telix Pharmaceuticals.
- Telix Pharmaceuticals grew revenue faster in its latest fiscal year (+55.61% vs +4.29%).
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
About Telix Pharmaceuticals
TLX stock →Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,120 employees
INDV vs TLX FAQ
Which is bigger, Indivior Pharmaceuticals or Telix Pharmaceuticals?
Indivior Pharmaceuticals (INDV) is larger, with a market capitalization of $4.18B compared with $3.74B for Telix Pharmaceuticals (TLX).
Which stock has performed better over the past year, INDV or TLX?
INDV returned +52.32% over the past 12 months, compared with +11.76% for TLX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, INDV or TLX?
INDV has the lower trailing P/E at 12.7, versus 110.1 for TLX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Indivior Pharmaceuticals and Telix Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.